NEW YORK, NY--(Marketwire -09/26/11)- IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK - News) (Pinksheets: SVFC.PK - News) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose-derived adult stem cells, announced today that it has executed an exclusive supply and sale agreement with Millipore Corporation, a global leader in innovative tools and technologies for bio-manufacturing and life science research, to sell and distribute the guava® flow cytometry platform into the area of SVF. This collaboration will streamline the development of IntelliCell's tissue processing centers throughout the United States as it continues to expand and experience growth in demand for the cells it is able to source from fatty tissue.
The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the U.S. FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, numerous doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments. In addition, numerous studies have been conducted on animals for veterinary applications over the last few decades.
"This is a phenomenal step in the right direction for our company and we welcome the opportunity to work with Millipore. The exclusive agreement with Millipore to supply and sell their cutting-edge guava flow cytometer, combined with our proprietary process which has achieved unprecedented yields of stromal vascular fraction without the use of chemical additives such as enzymes, gives us a highly significant advantage in creating the gold standard for the separation of SVF from fat. As the only company to use precise methods of counting cells and checking specimens for cell viability, dead cells, or debris, this is yet another milestone in our quest to become market leader in the area of separation of SVF, which greatly differentiates us from all other companies that manufacture these cells," stated IntelliCell Chairman and CEO, Dr. Steven Victor.
About IntelliCell Biosciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled "autologous homologous." IntelliCell has already established processing centers in Baton Rouge, New York City, Philadelphia, Dallas/Ft. Worth, Denver, Houston, New Orleans, Orlando, and West Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212 249 3050.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.